tetano
Editor, Senior Moderator
Biochem Pharmacol
. 2020 Jun 21;114114.
doi: 10.1016/j.bcp.2020.114114. Online ahead of print.
SARS-CoV-2 and Cardiovascular Complications: From Molecular Mechanisms to Pharmaceutical Management
Lin Wu[SUP] 1 [/SUP], Aislinn M O'Kane[SUP] 2 [/SUP], Hu Peng[SUP] 3 [/SUP], Yaguang Bi[SUP] 1 [/SUP], Dagmara Motriuk-Smith[SUP] 4 [/SUP], Jun Ren[SUP] 5 [/SUP]
Affiliations
Abstract
The coronavirus disease 2019 (COVID-19), elicited by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is a pandemic public health emergency of global concern. Other than the profound severe pulmonary damage, SARS-CoV-2 infection also leads to a series of cardiovascular abnormalities, including myocardial injury, myocarditis and pericarditis, arrhythmia and cardiac arrest, cardiomyopathy, heart failure, cardiogenic shock, and coagulation abnormalities. Meanwhile, COVID-19 patients with preexisting cardiovascular diseases are often at a much higher risk of increased morbidity and mortality. Up-to-date, a number of mechanisms have been postulated for COVID-19-associated cardiovascular damage including SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) activation, cytokine storm, hypoxemia, stress and cardiotoxicity of antiviral drugs. In this context, special attention should be given towards COVID-19 patients with concurrent cardiovascular diseases, and special cardiovascular attention is warranted for treatment of COVID-19.
Keywords: ACE2; COVID-19; Cardiovascular; Cytokine storm; SARS-CoV-2.
. 2020 Jun 21;114114.
doi: 10.1016/j.bcp.2020.114114. Online ahead of print.
SARS-CoV-2 and Cardiovascular Complications: From Molecular Mechanisms to Pharmaceutical Management
Lin Wu[SUP] 1 [/SUP], Aislinn M O'Kane[SUP] 2 [/SUP], Hu Peng[SUP] 3 [/SUP], Yaguang Bi[SUP] 1 [/SUP], Dagmara Motriuk-Smith[SUP] 4 [/SUP], Jun Ren[SUP] 5 [/SUP]
Affiliations
- PMID: 32579957
- PMCID: PMC7306106
- DOI: 10.1016/j.bcp.2020.114114
Abstract
The coronavirus disease 2019 (COVID-19), elicited by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is a pandemic public health emergency of global concern. Other than the profound severe pulmonary damage, SARS-CoV-2 infection also leads to a series of cardiovascular abnormalities, including myocardial injury, myocarditis and pericarditis, arrhythmia and cardiac arrest, cardiomyopathy, heart failure, cardiogenic shock, and coagulation abnormalities. Meanwhile, COVID-19 patients with preexisting cardiovascular diseases are often at a much higher risk of increased morbidity and mortality. Up-to-date, a number of mechanisms have been postulated for COVID-19-associated cardiovascular damage including SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) activation, cytokine storm, hypoxemia, stress and cardiotoxicity of antiviral drugs. In this context, special attention should be given towards COVID-19 patients with concurrent cardiovascular diseases, and special cardiovascular attention is warranted for treatment of COVID-19.
Keywords: ACE2; COVID-19; Cardiovascular; Cytokine storm; SARS-CoV-2.